Outcome of Board Meeting along with the results for the quarter ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong Q2 FY26 results with standalone net sales rising ~34% year-on-year to ₹14,358.53 lakhs (vs ₹10,689.19 lakhs in Q2 FY25). Standalone profit after tax nearly doubled to ₹973.23 lakhs (vs ₹427.33 lakhs), with EPS at ₹20.61 vs ₹9.05. For the half year (H1 FY26), standalone revenue grew ~42.6% to ₹26,298.82 lakhs and PAT jumped ~96% to ₹1,649.81 lakhs (vs ₹840.32 lakhs in H1 FY25). Operating profit before working capital changes improved sharply to ₹3,416 lakhs (vs ₹1,902 lakhs), and operating cash flow swung positive to ₹866.87 lakhs (vs negative ₹5,640.73 lakhs). Statutory auditor R.H. Nisar & Co issued an unmodified (clean) limited review report on both standalone and consolidated results. Consolidated results were also healthy, with H1 PAT of ₹1,619.74 lakhs. No exceptional items were reported.
A robust topline and bottomline beat, with revenue growing over 40% YoY in H1 and PAT nearly doubling, signals strong business momentum for shareholders. Improved operating cash flow and clean auditor opinion are positive for sentiment, though finance costs remain elevated (₹1,426 lakhs in H1), keeping the stock on watch for margin sustainability.